CSBR Stock Overview
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
NewNotes are coming soon
Champions Oncology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.05 |
| 52 Week High | US$9.88 |
| 52 Week Low | US$3.75 |
| Beta | 0.98 |
| 1 Month Change | -6.25% |
| 3 Month Change | -42.80% |
| 1 Year Change | -48.08% |
| 3 Year Change | -46.64% |
| 5 Year Change | 12.50% |
| Change since IPO | -66.25% |
Recent News & Updates
Recent updates
Is Now The Time To Put Champions Oncology (NASDAQ:CSBR) On Your Watchlist?
Sep 28
We Think Some Shareholders May Hesitate To Increase Champions Oncology, Inc.'s (NASDAQ:CSBR) CEO Compensation
Oct 14We Think Champions Oncology (NASDAQ:CSBR) Can Afford To Drive Business Growth
Jun 21Are Investors Undervaluing Champions Oncology, Inc. (NASDAQ:CSBR) By 44%?
Apr 09Here's Why We're Not At All Concerned With Champions Oncology's (NASDAQ:CSBR) Cash Burn Situation
Mar 19The Champions Oncology (NASDAQ:CSBR) Share Price Has Gained 243%, So Why Not Pay It Some Attention?
Mar 02Is There Now An Opportunity In Champions Oncology, Inc. (NASDAQ:CSBR)?
Feb 04Do Insiders Own Lots Of Shares In Champions Oncology, Inc. (NASDAQ:CSBR)?
Jan 14Philip Breitfeld Is The Chief Strategy & Innovation Officer and Director of Champions Oncology, Inc. (NASDAQ:CSBR) And They Just Sold 100% Of Their Shares
Dec 19Champions Oncology, Inc. (NASDAQ:CSBR) Analysts Are Pretty Bullish On The Stock After Recent Results
Dec 16
Estimating The Fair Value Of Champions Oncology, Inc. (NASDAQ:CSBR)
Dec 04Shareholder Returns
| CSBR | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | -0.7% | -1.1% | 2.3% |
| 1Y | -48.1% | -9.3% | -9.7% |
Return vs Industry: CSBR underperformed the US Life Sciences industry which returned -6.9% over the past year.
Return vs Market: CSBR underperformed the US Market which returned -8.5% over the past year.
Price Volatility
| CSBR volatility | |
|---|---|
| CSBR Average Weekly Movement | 15.6% |
| Life Sciences Industry Average Movement | 11.8% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 17.3% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CSBR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: CSBR's weekly volatility has increased from 9% to 16% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1985 | 230 | Ronnie Morris | https://www.championsoncology.com |
Champions Oncology, Inc. develops and sells technology solutions and products to personalize the development and use of oncology drugs in the United States. Its Tumorgraft Technology Platform is an approach to personalizing cancer care based upon the implantation of human tumors in immune-deficient mice. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice.
Champions Oncology, Inc. Fundamentals Summary
| CSBR fundamental statistics | |
|---|---|
| Market Cap | US$54.91m |
| Earnings (TTM) | US$108.00k |
| Revenue (TTM) | US$54.10m |
508.4x
P/E Ratio1.0x
P/S RatioIs CSBR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CSBR income statement (TTM) | |
|---|---|
| Revenue | US$54.10m |
| Cost of Revenue | US$27.12m |
| Gross Profit | US$26.97m |
| Other Expenses | US$26.87m |
| Earnings | US$108.00k |
Last Reported Earnings
Oct 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.008 |
| Gross Margin | 49.86% |
| Net Profit Margin | 0.20% |
| Debt/Equity Ratio | 0% |
How did CSBR perform over the long term?
See historical performance and comparison